<DOC>
	<DOCNO>NCT01795664</DOCNO>
	<brief_summary>This study conduct randomize , double blind , double dummy two period crossover study stable asthma patient . A total 16 stable asthma patient treat accordance Global Initiative Asthma ( GINA ) guideline , include . Objectives : - The primary objective study evaluate effect study drug investigation Functional Respiratory Imaging ( FRI ) parameter evaluate particle deposition lung use Computational Fluid Dynamic ( CFD ) - The secondary objective assess effect study drug lung function ( spirometry body plethysmography ) , exercise capacity ( 6 Minutes Walking Test = 6MWT ) dyspnea ( Borg Category ( C ) Ratio ( R ) 10 Scale Visual Analog Scale ( VAS ) dyspnea ) . Furthermore safety 2 product investigation evaluate monitoring adverse event ( AEs ) throughout study .</brief_summary>
	<brief_title>Compare Effects Seretide® Evohaler Generic Salmeterol/Fluticasone Hydrofluoroalkane ( HFA ) Pressurized Metered-dose Inhaler ( pMDI ) Functional Respiratory Imaging Parameters Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Male female patient ≥ 18 year old Written inform consent obtain Patient document diagnosis asthma accord GINA guideline Patient cooperative attitude ability train correctly use pMDI Female patient childbearing potential confirm contraception method use least 14 day visit 1 continue use contraception method study Patient must stable treated accordance GINA guideline Patient must nonsmoker exsmoker stop smoke least 1 year prior visit 1 smoke history &lt; 10 pack year Patient must able understand complete protocol requirement , instruction , questionnaire protocolstated restriction Pregnant lactate female Unstable patient develop exacerbation last 8 week Patient upper low airway infection Patient unable carry pulmonary function test Patient uncontrolled disease condition might , judgement investigator , place patient undue risk potentially compromise result interpretation study Patient cancer chronic disease poor prognosis /or affect patient status Patient allergy , sensitivity intolerance study drug and/or study drug formulation ingredient Patient unlikely comply protocol unable understand nature , scope possible consequence study Patient receive oral corticosteroid within last 4 week prior visit 1 Patient receive investigational new drug within last 4 week prior visit 1 twice duration biological effect drug ( whichever longer ) Patient history alcohol substance abuse opinion investigator may clinical significance Patient undergone major surgery last 12 week visit 1 plan undergo major surgery end trial Patient diagnosis chronic obstructive pulmonary disease ( COPD )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Salmeterol xinafoate Fluticasone propionate</keyword>
	<keyword>Seretide Evohaler</keyword>
	<keyword>Functional Respiratory Imaging</keyword>
	<keyword>Computational Fluid Dynamic</keyword>
</DOC>